Clinical Trials Logo

Clinical Trial Summary

This is a single-arm, open-label, dose ramp-up exploratory clinical trial to evaluate the efficacy, safety and tolerance of aerosol inhalation of FB2001 as post-exposure prophylaxis among close contacts of COVID-19 patients. This study will enroll 20 to 60 close contacts of COVID-19 patients aging 18 to 65 years. After signing the informed consent form, the qualified subjects will be given FB2001 once or twice daily.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05415241
Study type Interventional
Source Ruijin Hospital
Contact Jieming Qu, PhD
Phone 0086-021-64370045
Email jmqu0906@163.com
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date June 9, 2022
Completion date December 31, 2022